Biovica says DiviTum TKa study in metastatic melanoma is published in Clinical Cancer Research

• Biovica reported peer-reviewed Clinical Cancer Research publication on DiviTum TKa use in metastatic melanoma patients in the Phase II SECOMBIT trial.
• Results were presented as newly published findings, not flagged for a future conference presentation.
• Lower pre-treatment TKa was linked to better long-term outcomes, supporting use in upfront risk stratification.
• Higher pre-treatment TKa favored a sequence starting with short targeted therapy, then immunotherapy, versus other sequencing approaches.
• Rising TKa during therapy tracked with disease progression, supporting a potential role in ongoing response monitoring.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovica International AB published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein.